Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products

References

• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017 Oct 19;130(16):1800–1808. PubMed PMID: 28774879; PubMed Central PMCID: PMCPMC5649550. eng.
   PubMed Web of Science ®Google Scholar
• Seshadri T, Stakiw J, Pintilie M, et al. Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy. Hematology. 2008 Oct;13(5):261–266. PubMed PMID: 18854087; eng.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol. 2005 Aug;130(3):363–372. PubMed PMID: 16042685; eng.
   PubMed Web of Science ®Google Scholar
• Telio D, Fernandes K, Ma C, et al. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma. 2012 May;53(5):836–841. PubMed PMID: 22136378; eng.
   PubMed Web of Science ®Google Scholar
• Sirvent A, Dhedin N, Michallet M, et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant. 2010 Jan;16(1):78–85. PubMed PMID: 19744569; eng.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010 Jan;16(1):35–45. PubMed PMID: 20053330; PubMed Central PMCID: PMCPMC2929576. eng.
   PubMed Web of Science ®Google Scholar
• Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012 Nov 15;120(20):4256–4262. PubMed PMID: 23007405; PubMed Central PMCID: PMCPMC3501720. eng.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Ahn KW, Graff TM, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016 Jul;174(2):235–248. PubMed PMID: 26989808; PubMed Central PMCID: PMCPMC4940282. eng.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010 Nov 18;116(20):4099–4102. PubMed PMID: 20668228; PubMed Central PMCID: PMCPMC2993617. eng.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015 Feb 20;33(6):540–549. PubMed PMID: 25154820; PubMed Central PMCID: PMCPmc4322257. eng.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544. 10.1056/NEJMoa1707447. PubMed PMID: 29226797; PubMed Central PMCID: PMCPmc5882485. eng.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019 Jan 3;380(1):45–56. PubMed PMID: 30501490; eng.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Siddiqi T, Palomba ML, et al. High durable CR rates and prelinary safety profile for JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 Study): a defined composition CD19-direted CAR T-cell product with potential for outpatient administration. J Clin Oncol. 2018;(36).
   Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018 Jul 5;379(1):64–73. PubMed PMID: 29972754; eng.
   PubMed Web of Science ®Google Scholar
• Lichtman EI, Dotti G. Chimeric antigen receptor T-cells for B-cell malignancies. Transl Res. 2017 Sep;187:59–82. PubMed PMID: 28719798; eng.
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011 Jul 1;71(13):4617–4627. PubMed PMID: 21546571; PubMed Central PMCID: PMCPMC4140173. eng.
   PubMed Web of Science ®Google Scholar
• Holzinger A, Barden M, Abken H. The growing world of CAR T cell trials: a systematic review. Cancer Immunol Immunother. 2016 Dec;65(12):1433–1450. 10.1007/s00262-016-1895-5. PubMed PMID: 27613725; eng.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan;20(1):31–42. PubMed PMID: 30518502; eng.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Puccini B, Dodero A, et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol. 2012 Jun;91(6):931–939. PubMed PMID: 22245922; eng.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Saber W, Ahn KW, et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013 May;19(5):746–753. PubMed PMID: 23380340; PubMed Central PMCID: PMCPMC3650915. eng.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment [Review]. Cell Death Dis. 2015 June 18;6:e1792.
   PubMed Web of Science ®Google Scholar
• Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR. Blood. 2017;129(8):1039–1041.
   PubMed Web of Science ®Google Scholar
• Chong EA, Svoboda J, Nasta SD, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-hodgkin lymphomas. Blood. 2018;132. DOI:10.1182/blood-2018-99-119502.
   PubMedGoogle Scholar
• Jacobson CA, Locke FL, Miklos DB, et al. End of Phase 1 results from Zuma-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma. Blood. 2018;132(Suppl 1):4192.
   Google Scholar
• Rupp LJ, Schumann K, Roybal KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017 April 07;7(1):737. .
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015 Dec;5(12):1282–1295. PubMed PMID: 26516065; PubMed Central PMCID: PMCPmc4670800. eng.
   PubMed Web of Science ®Google Scholar
• Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019 Apr;568(7750):112–116. 10.1038/s41586-019-1054-1. PubMed PMID: 30918399; eng.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Rietberg SP, Labanieh L, et al. Low CD19 antigen density diminishes efficacy of CD19 CAR T cells and can be overcome by rational redesign of CAR signaling domains. Blood. 2018;132. DOI:10.1182/blood-2018-99-115558.
   PubMed Web of Science ®Google Scholar
• Boucher JC, Li G, Shrestha B, et al. Mutation of the CD28 costimulatory domain confers decreased CAR T cell exhaustion. Blood. 2018;132:966.
   Web of Science ®Google Scholar
• Schultz LM, Davis KL, Baggott C, et al. Phase 1 study of CD19/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell Acute Lymphoblastic Leukemia (ALL). Blood. 2018;132:898.
   Google Scholar
• Shah NN, Zhu F, Taylor C, et al. A Phase 1 study with point-of-care manufacturing of deal targeted, tandem anti-CD19, anti-CD20 chimeric antigen receptor modified T (CAR-T) cells for relapsed, refractory, non-Hodgkin lymphoma. Blood. 2018;132:4193.
   Web of Science ®Google Scholar
• Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016 Mar 3;127(9):1117–1127. PubMed PMID: 26813675; PubMed Central PMCID: PMCPMC4778162. eng.
   PubMed Web of Science ®Google Scholar
• Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017 Nov 23;130(21):2295–2306. PubMed PMID: 28924019; PubMed Central PMCID: PMCPMC5701525. eng.
   PubMed Web of Science ®Google Scholar
• Gill SI, Vides V, Frey NV, et al. Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate. Blood. 2018;132: 10.1182/blood-2018-99-115418.
   PubMedGoogle Scholar
• Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015 Sep 2;7(303):303ra139. PubMed PMID: 26333935; PubMed Central PMCID: PMCPmc5909068. eng.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188–195. PubMed PMID: 24876563; PubMed Central PMCID: PMCPmc4093680. eng.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509–1518. PubMed PMID: 23527958; PubMed Central PMCID: PMCPmc4058440. eng.
   PubMed Web of Science ®Google Scholar
• Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019 Feb 11. PubMed PMID: 30753567; eng. DOI:10.1093/jnci/djz017
   Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25. PubMed PMID: 24553386; PubMed Central PMCID: PMCPmc4684949. eng.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Khaled SK, Budde E, et al. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: pathophysiology, Prevention, and Treatment. Curr Oncol Rep. 2019 Jan 21;21(1):4. 10.1007/s11912-019-0753-y. PubMed PMID: 30666425; eng.
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Knop S, Viardot A, et al. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: final Results From a Phase I Study. J Clin Oncol. 2016 Apr 1;34(10):1104–1111. PubMed PMID: 26884582; eng.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013 Jun 27;121(26):5154–5157. PubMed PMID: 23678006; PubMed Central PMCID: PMCPMC4123427. eng.
   PubMed Web of Science ®Google Scholar
• Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996 Dec 15;98(12):2819–2826. PubMed PMID: 8981930; PubMed Central PMCID: PMCPMC507749. eng.
   PubMed Web of Science ®Google Scholar
• Raj RV, Hamadani M, Szabo A, et al. Peripheral blood grafts for T cell-replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome. Biol Blood Marrow Transplant. 2018 Aug;24(8):1664–1670. PubMed PMID: 29680516; eng.
   PubMed Web of Science ®Google Scholar
• Abboud R, Keller J, Slade M, et al. Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016 Oct;22(10):1851–1860. PubMed PMID: 27318038; PubMed Central PMCID: PMCPMC5070661. eng.
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett D, Teachey DT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119–122. Mar-Apr;():. doi: . PubMed PMID: 24667956; PubMed Central PMCID: PMCPMC4119809. eng.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Hunter B, Armand P, et al. Axicabtagene ciloleucel in the real world: outcomes and predictors of reponse, resistance, and toxicity. Blood. 2018;132:92.
   Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL). Blood. 2017;abstract 130.
   Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan;15(1):47–62. PubMed PMID: 28925994; eng.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008 Nov 15;112(10):3959–3964. PubMed PMID: 18784373; eng.
   PubMed Web of Science ®Google Scholar
• Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018 Aug;8(8):958–971. PubMed PMID: 29880584; eng.
   PubMed Web of Science ®Google Scholar
• Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018 Jun;24(6):739–748. 10.1038/s41591-018-0036-4. PubMed PMID: 29808007; eng.
   PubMed Web of Science ®Google Scholar
• Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018 Jun;24(6):731–738. 10.1038/s41591-018-0041-7. PubMed PMID: 29808005; eng.
   PubMed Web of Science ®Google Scholar
• Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017 Dec;7(12):1404–1419. PubMed PMID: 29025771; PubMed Central PMCID: PMCPMC5718945. eng.
   PubMed Web of Science ®Google Scholar
• Torre M, Solomon IH, Sutherland CL, et al. Neuropathology of a case with fatal CAR T-cell-associated cerebral edema. J Neuropathol Exp Neurol. 2018 Oct 1;77(10):877–882. PubMed PMID: 30060228; eng.
   PubMed Web of Science ®Google Scholar
• Taraseviciute A, Tkachev V, Ponce R, et al. Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 2018 Jun;8(6):750–763. PubMed PMID: 29563103; PubMed Central PMCID: PMCPMC6058704. eng.
   PubMed Web of Science ®Google Scholar
• Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med. 2018 May;66(2):50–52. PubMed PMID: 29625831; PubMed Central PMCID: PMCPMC5967886. eng.
   PubMed Web of Science ®Google Scholar
• Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133(7):697–709. PubMed PMID: 30463995; PubMed Central PMCID: PMCPMC6376281. eng.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Smith AR, Triplett BM, et al. Defibrotide for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome: interim results from a treatment IND study. Biol Blood Marrow Transplant. 2017 Jun;23(6):997–1004. PubMed PMID: 28285079; eng.
   PubMed Web of Science ®Google Scholar
• Helsen CW, Hammill JA, Lau VWC, et al. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nat Commun. 2018 Aug 3;9(1):3049. 10.1038/s41467-018-05395-y. PubMed PMID: 30076299; PubMed Central PMCID: PMCPMC6076291. eng.
   PubMed Web of Science ®Google Scholar
• Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017 Mar 2;543(7643):113–117. PubMed PMID: 28225754; PubMed Central PMCID: PMCPMC5558614. eng.
   PubMed Web of Science ®Google Scholar
• Roybal KT, Williams JZ, Morsut L, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell. 2016 Oct 6;167(2):419–432 e16. PubMed PMID: 27693353; PubMed Central PMCID: PMCPMC5072533. eng.
   PubMed Web of Science ®Google Scholar
• Hernandez I, Prasad V, Gellad WF. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 2018 Jul 1;4(7):994–996. PubMed PMID: 29710129; PubMed Central PMCID: PMCPMC6145722. eng.
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma. JAMA Network Open. 2019 Feb 1;2(2):e190035. PubMed PMID: 30794298; eng.
   PubMed Web of Science ®Google Scholar
• Sarkar RR, Gloude NJ, Schiff D, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic Leukemia. J Natl Cancer Inst. 2018 Dec 14 PubMed PMID: 30551196; eng. doi:10.1093/jnci/djy193.
   PubMedGoogle Scholar
• Lin J, Lerman B, Barnes J, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018;2018(Sep):13.
   Google Scholar
• Benjamin R, Graham C, Yallop D, et al. Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia. Blood. 2018;132:896..
   Web of Science ®Google Scholar